These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11392158)

  • 1. [Hyperhomocysteinemia as a risk factor for cardiovascular diseases in patients with chronic renal failure].
    Małecki R
    Pol Arch Med Wewn; 2000 Oct; 104(4):695-701. PubMed ID: 11392158
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hyperhomocysteinemia in chronic renal failure].
    Sydor A; Sułowicz W
    Przegl Lek; 1999; 56(7-8):520-4. PubMed ID: 10575921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies.
    Perna AF; Sepe I; Lanza D; Pollastro RM; De Santo NG; Ingrosso D
    J Ren Nutr; 2012 Jan; 22(1):191-4. PubMed ID: 22200441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal insufficiency is an important cardiovascular risk factor].
    Pérez Flores I; Luño J
    Nefrologia; 2002; 22(4):306-9. PubMed ID: 12369120
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging cardiovascular risk factors in end-stage renal disease.
    Yaqoob MM
    J Nephrol; 2002; 15(2):205-8. PubMed ID: 12018642
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
    Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
    Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperhomocysteinemia as a risk factor for cardiovascular diseases. The association of hyperhomocysteinemia with diabetes mellitus and renal transplant recipients.
    Socha MW; Polakowska MJ; Socha-Urbanek K; Fiedor P
    Ann Transplant; 1999; 4(1):11-9. PubMed ID: 10850596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocysteinemia and vascular disease: role and implications.
    Yeolekar ME; Bichile SK; Shete MM
    J Assoc Physicians India; 2002 May; 50 Suppl():5-8. PubMed ID: 12186156
    [No Abstract]   [Full Text] [Related]  

  • 9. Homocysteine targeting of plasma proteins in hemodialysis patients.
    Jacobsen DW
    Kidney Int; 2006 Mar; 69(5):787-9. PubMed ID: 16518339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperhomocysteinemia in end-stage renal failure.
    Kes P
    Acta Med Croatica; 2000; 54(4-5):175-81. PubMed ID: 11379482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhomocysteinemia and cardiovascular risks in hemodialysis patients.
    Sagheb MM; Ostovan MA; Sohrabi Z; Atabati E; Raisjalai GA; Roozbeh J
    Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):863-6. PubMed ID: 20814121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhomocysteinemia in chronic renal disease.
    Bostom AG; Culleton BF
    J Am Soc Nephrol; 1999 Apr; 10(4):891-900. PubMed ID: 10203375
    [No Abstract]   [Full Text] [Related]  

  • 13. How can the cardiac death rate be reduced in dialysis patients?
    Avram MM
    Semin Dial; 2002; 15(1):26-9. PubMed ID: 11874588
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular disease in patients with chronic kidney disease. A clinical review.
    Kaisar M; Isbel N; Johnson DW
    Minerva Urol Nefrol; 2007 Sep; 59(3):281-97. PubMed ID: 17912225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients.
    Fellah H; Feki M; Hsairi M; Sanhaji H; Kaabachi N; Ben Abdallah T; Massy ZA; Ben Maiz H; Lacour B; Mebazaa A
    Clin Chem Lab Med; 2003 May; 41(5):675-80. PubMed ID: 12812266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of a supplementation with vitamins on cardiovascular morbidity and mortality in patients with end-stage renal disease: design and baseline data of a randomized clinical trial.
    Heinz J; Domröse U; Luley C; Westphal S; Kropf S; Neumann KH; Dierkes J
    Clin Nephrol; 2009 Mar; 71(3):363-5. PubMed ID: 19281755
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a reversal of reverse epidemiology in renal transplant recipients?
    Chavalitdhamrong D; Danovitch GM; Bunnapradist S
    Semin Dial; 2007; 20(6):544-8. PubMed ID: 17991202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney disease as an independent risk factor for cardiovascular events.
    Kumar J; Shah SV
    J Ren Nutr; 2005 Jan; 15(1):99-104. PubMed ID: 15648016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperhomocysteinemia after kidney transplantation.
    Einollahi B; Lessan-Pezeshki M; Kalantar E; Rostami Z; Khalili N; Ghadiani MH; Ahmadi J
    Transplant Proc; 2011 Mar; 43(2):586-7. PubMed ID: 21440769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.
    Wrone EM; Zehnder JL; Hornberger JM; McCann LM; Coplon NS; Fortmann SP
    Kidney Int; 2001 Sep; 60(3):1106-13. PubMed ID: 11532106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.